These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 7903100)

  • 1. Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability.
    Rodrigues ML; Snedecor B; Chen C; Wong WL; Garg S; Blank GS; Maneval D; Carter P
    J Immunol; 1993 Dec; 151(12):6954-61. PubMed ID: 7903100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High level expression of chimeric antibody fragment F(ab')2 directed against CD20 in Escherichia coli].
    Xiong DS; Zheng MJ; Liu YX; Xu YF; Wang JH; Yang CZ
    Sheng Wu Gong Cheng Xue Bao; 2004 Sep; 20(5):673-8. PubMed ID: 15973988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
    Glennie MJ; McBride HM; Worth AT; Stevenson GT
    J Immunol; 1987 Oct; 139(7):2367-75. PubMed ID: 2958547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen.
    Temponi M; Gold AM; Ferrone S
    Cancer Res; 1992 May; 52(9):2497-503. PubMed ID: 1373670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity.
    Zapata G; Ridgway JB; Mordenti J; Osaka G; Wong WL; Bennett GL; Carter P
    Protein Eng; 1995 Oct; 8(10):1057-62. PubMed ID: 8771187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.
    Leung SO; Qu Z; Hansen HJ; Shih LB; Wang J; Losman MJ; Goldenberg DM; Sharkey RM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3106s-3117s. PubMed ID: 10541351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies.
    Holton OD; Black CD; Parker RJ; Covell DG; Barbet J; Sieber SM; Talley MJ; Weinstein JN
    J Immunol; 1987 Nov; 139(9):3041-9. PubMed ID: 3499463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
    Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT
    J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies.
    Daha MR; Bloem AC; Ballieux RE
    J Immunol; 1984 Mar; 132(3):1197-1201. PubMed ID: 6229578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
    Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
    Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
    Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa].
    Mazurov AV; Pevzner DV; Khaspekova SG; Dudnik OA; Byzova TV; Vlasik TN; Bakharev VN; Pistsov MIu; Staroverov II; Ruda MIa
    Ter Arkh; 2001; 73(9):66-73. PubMed ID: 11642086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
    Covell DG; Barbet J; Holton OD; Black CD; Parker RJ; Weinstein JN
    Cancer Res; 1986 Aug; 46(8):3969-78. PubMed ID: 3731067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
    King DJ; Turner A; Farnsworth AP; Adair JR; Owens RJ; Pedley RB; Baldock D; Proudfoot KA; Lawson AD; Beeley NR
    Cancer Res; 1994 Dec; 54(23):6176-85. PubMed ID: 7954464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.
    Better M; Bernhard SL; Lei SP; Fishwild DM; Lane JA; Carroll SF; Horwitz AH
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):457-61. PubMed ID: 7678457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent modifications of antitetanus F(ab')2 fragments with natural and synthetic polyamines and their effects on the antibody endocytosis in cultured HL60 cells.
    Hervé F; Ghinea N; D'Athis P; Carrupt PA; Scherrmann JM
    Bioconjug Chem; 2008 Aug; 19(8):1543-55. PubMed ID: 18630939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.